Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1
- Registration Number
- NCT01467414
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01437592
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 413
- Registration Number
- NCT01392573
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, St. Gallen, Switzerland
Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin
- Conditions
- Interventions
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 413
- Registration Number
- NCT01388361
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT01364428
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Renton, Washington, United States
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1663
- Registration Number
- NCT01336023
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2011-03-30
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 222
- Registration Number
- NCT01326026
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Pozuelo de Alarcon, Spain
Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01319240
Comparison of Two Identical NN1250 Formulations in Healthy Volunteers
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 26
- Registration Number
- NCT01193387
Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-08-02
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT01173926
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.